RE:RE:RE:RE:Thoughts on why our phase II targeted a 40% efficacy....Most intelligent post I've read on that bullboard since I started to read them...I couldn't agree more with you : this bullboard is infected by idiots.
Your point on the off-label use due to BCG shortage is very interesting. Make a lot of sense since urologists seems to support MCNA.
If the approved FDA indication only cuts "papillary tumors only" and "fit people willing to undergo cystectomy", that's not too bad.
Best regards,
M80